SCHEMBL7204544

SCHEMBL7204544

NC(=O)N1CCC(S(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 11/20 0.41
MMP13 P45452 11/20 0.41
ADAMTS4 O75173 4/20 0.41
MAPT P10636 1/20 0.40
MMP3 P08254 5/20 0.38
MMP8 P22894 3/20 0.38
MMP9 P14780 9/20 0.38
MMP2 P08253 7/20 0.38
ADAM17 P78536 4/20 0.38
MMP14 P50281 4/20 0.37
MMP12 P39900 2/20 0.37
MMP7 P09237 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
LTA4H P09960 1/20 0.36
FAAH O00519 1/20 0.36
MGLL Q99685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207163 0.92 MMP1 (0.45) MMP1MMP13MAPTMMP3MMP8
SCHEMBL7204066 0.90 ALDH1A1 (0.38) MMP1MMP13ADAMTS4MMP3MMP8
SCHEMBL7199646 0.90 MMP1 (0.43) MMP1MMP13MAPTMMP3MMP8
SCHEMBL7204562 0.90 MMP13 (0.51) MMP1MMP13ADAMTS4MAPTMMP3
SCHEMBL7203058 0.90 MMP9 (0.47) MMP1MMP13MAPTMMP3MMP8
SCHEMBL7199692 0.90 PARP10 (0.41) MMP1MMP13MMP3MMP8MMP9
SCHEMBL7203051 0.89 MMP1 (0.39) MMP1MMP13MMP3MMP8MMP9
SCHEMBL7205347 0.88 MMP1 (0.56) MMP1MMP13ADAMTS4MAPTMMP3
SCHEMBL7199700 0.87 MMP1 (0.42) MMP1MMP13ADAMTS4ALDH1A1FAAH
SCHEMBL7208203 0.85 MMP13 (0.41) MMP1MMP13ADAMTS4MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAMTS4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.